학술논문
Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
Document Type
article
Author
Brigitte Michelsen; Mikkel Østergaard; Michael John Nissen; Adrian Ciurea; Burkhard Möller; Lykke Midtbøll Ørnbjerg; Jakub Zavada; Bente Glintborg; Alan MacDonald; Karin Laas; Dan Nordström; Bjorn Gudbjornsson; Florenzo Iannone; Pasoon Hellmand; Tore Kristian Kvien; Ana Maria Rodrigues; Catalin Codreanu; Ziga Rotar; Isabel Castrejón Fernández; Johan Karlsson Wallman; Jiri Vencovsky; Anne Gitte Loft; Maureen Heddle; Sigrid Vorobjov; Anna-Mari Hokkanen; Gerdur Gröndal; Marco Sebastiani; Marleen van de Sande; Eirik Klami Kristianslund; Maria José Santos; Corina Mogosan; Matija Tomsic; Federico Díaz-González; Daniela Di Giuseppe; Merete Lund Hetland
Source
The Lancet Regional Health. Europe, Vol 33, Iss , Pp 100706- (2023)
Subject
Language
English
ISSN
2666-7762
Abstract
Summary: This is the first report comparing EULAR and national treatment recommendations for PsA patients across Europe, and the first this decade to compare ASAS-EULAR and national treatment recommendations in axSpA patients. An electronic survey was completed from October 2021–April 2022 by rheumatologists in 15 European countries. One and four countries followed all EULAR and ASAS-EULAR recommendations, respectively. Five countries had no national treatment recommendations for PsA and/or axSpA, but followed other regulations. In several countries, national treatment recommendations predated the most recent EULAR/ASAS-EULAR recommendations. Entry criteria for starting biologic/targeted synthetic disease-modifying anti-rheumatic drugs varied considerably. In several countries, for PsA patients with significant skin involvement, interleukin-17 inhibitors were not given preference. The positioning of Janus Kinase inhibitors differed and Phosphodiesterase-4 inhibitors were not in use/reimbursed in most countries. This study may motivate European countries to update their national treatment recommendations, to align them better with the latest international recommendations.